
RECOMMENDATIONS

- From the results of this study, it is recommended to periodically follow up chronic Hepatitis C patients with genotype 4 for glucose abnormalities and anticipate their occurrence.
- Implementation of new guidelines in Hepatitis C genotype 4 treatment, involving pretreatment screening for insulin resistance using HOMA-IR test, being an easy and practical one.
- Studies determining cut off value for HOMA-IR test as a definitive method for determining insulin resistance in Egyptian patients with genotype 4.
- Considering management of insulin resistance in patients who are candidates for treatment using dual therapy pegIFN/RBV, through lifestyle modification or even using antidiabetics as metformin.
- Large studies are needed to test the effect of insulin resistance on new treatment modalities using the newly approved DAA drugs as sofosbuvir and ledipasvir.
- Further studies are needed to establish the direct role of HCV in development of insulin resistance in chronic hepatitis C patients addressing multiple pathways.
- More studies are needed to follow up the treated patients who showed insulin resistance, for a longer period of time after stopping treatment to rule out rebound or increase in HOMA-IR.
- Larger studies with larger studied population are needed to confirm the metabolic role in development of insulin resistance in CHC patients.
- Follow up studies for the effect of insulin resistance on liver functions and fibrosis progression, are needed.

REFERENCES

1. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. *World journal of gastroenterology : WJG.* 2014;20(29):9633-52.
2. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. *World journal of gastroenterology : WJG.* 2014;20(28):9270-80.
3. Structural biology of the hepatitis C virus proteins. *Drug discovery today Technologies.* 2012;9(3):e175-226.
4. Fraser CS, Doudna JA. Structural and mechanistic insights into hepatitis C viral translation initiation. *Nature reviews Microbiology.* 2007;5(1):29-38.
5. Afzal MS, Alsaleh K, Farhat R, Belouzard S, Danneels A, Descamps V, *et al.* Regulation of core expression during the hepatitis C virus life cycle. *The Journal of general virology.* 2014.
6. Irshad M, Dhar I. Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. *Medical principles and practice : international journal of the Kuwait University, Health Science Centre.* 2006;15(6):405-16.
7. Popescu CI, Riva L, Vlaicu O, Farhat R, Rouille Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. *Biology.* 2014;3(4):892-921.
8. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, *et al.* Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. *Journal of clinical microbiology.* 2005;43(4):1902-9.
9. Hussein N, Zekri AN, Abouelhoda M, Alam El-Din HM, Ghamry A, Amer MA, *et al.* New insight into HCV E1/E2 region of genotype 4a. *Virology journal.* 2014;11(1):2512.
10. Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, *et al.* Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. *Journal of virology.* 2014;88(24):14278-88.
11. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle - An update. *Journal of hepatology.* 2014;61(1S):S3-S13.
12. Araujo AC. Antibody- and genome-based identification of recent HCV infection. *Antiviral therapy.* 2012;17(7 Pt B):1459-64.
13. Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. Sequencing of the Hepatitis C Virus: A Systematic Review. *PloS one.* 2013;8(6):e67073.
14. Khudyakov Y. Molecular surveillance of hepatitis C. *Antiviral therapy.* 2012;17(7 Pt B):1465-70.
15. Liang Y, Kang CB, Yoon HS. Molecular and structural characterization of the domain 2 of hepatitis C virus non-structural protein 5A. *Molecules and cells.* 2006;22(1):13-20.
16. Elsadek Fakhr A, Pourkarim MR, Maes P, Atta AH, Marei A, Azab M, *et al.* Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt. *Hepatitis monthly.* 2013;13(12):e12706.
17. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. *Journal of hepatology.* 2014;61(1S):S14-S25.
18. Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. *World journal of gastroenterology : WJG.* 2013;19(44):7896-909.

19. Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. *Frontiers in immunology*. 2014;5:550.
20. Kolls JK, Szabo G. The genetics of hepatitis C virus underlie its ability to escape humoral immunity. *The Journal of clinical investigation*. 2014:1-2.
21. Howell J, Angus P, Gow P, Visvanathan K. Toll-like receptors in hepatitis C infection: implications for pathogenesis and treatment. *Journal of gastroenterology and hepatology*. 2013;28(5):766-76.
22. Martinez-Donato G, Amador-Canizares Y, Alvarez-Lajonchere L, Guerra I, Perez A, Dubuisson J, *et al*. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation. *Vaccine*. 2014;32(15):1720-6.
23. McWilliam Leitch EC, McLauchlan J. Determining the cellular diversity of hepatitis C virus quasispecies by single-cell viral sequencing. *Journal of virology*. 2013;87(23):12648-55.
24. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, *et al*. Historical epidemiology of hepatitis C virus (HCV) in selected countries. *Journal of viral hepatitis*. 2014;21 Suppl 1:5-33.
25. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *Journal of hepatology*. 2014;61(1S):S45-S57.
26. Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. *Best practice & research Clinical gastroenterology*. 2012;26(4):413-27.
27. Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. *Infectious disease clinics of North America*. 2012;26(4):995-1010.
28. Cho YK, Kim YN, Song BC. Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. *Clinical and molecular hepatology*. 2014;20(4):368-75.
29. Chevaliez S. New markers for diagnosis and management of chronic hepatitis C virus infection. *Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology*. 2013;26(2):98-9.
30. Yamane D, McGivern DR, Masaki T, Lemon SM. Liver injury and disease pathogenesis in chronic hepatitis C. *Current topics in microbiology and immunology*. 2013;369:263-88.
31. Gomes MA, Prioli DG, Tralhao JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. *Revista da Associacao Medica Brasileira*. 2013;59(5):514-24.
32. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. *Journal of hepatology*. 2014;61(1S):S79-S90.
33. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. *International journal of cancer Journal international du cancer*. 2009;124(3):690-7.
34. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. *Journal of viral hepatitis*. 2015;22 Suppl 1:1-5.
35. Nagao Y, Kawaguchi T, Tanaka K, Kumashiro R, Sata M. Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area. *International journal of molecular medicine*. 2005;16(2):291-6.

36. Saraswat V, Norris S, de Knecht RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, *et al.* Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. *Journal of viral hepatitis*. 2015;22 Suppl 1:6-25.
37. Dibonaventura MD, Yuan Y, Lescrauwaet B, L'Italien G, Liu GG, Kamae I, *et al.* Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. *PloS one*. 2014;9(1):e86070.
38. Kim KA, Jeong SH, Jang ES, Kim YS, Lee YJ, Jung EU, *et al.* Geographic differences in the epidemiological features of HCV infection in Korea. *Clinical and molecular hepatology*. 2014;20(4):361-7.
39. Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, *et al.* Towards realistic estimates of HCV incidence in Egypt. *Journal of viral hepatitis*. 2013;20(4):294-6.
40. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. *Journal of viral hepatitis*. 2012;19(8):560-7.
41. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. *BMC infectious diseases*. 2013;13:288.
42. Cuadros DF, Branscum AJ, Miller FD, Abu-Raddad LJ. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. *Hepatology*. 2014;60(4):1150-9.
43. Miller FD, Abu-Raddad LJ. Quantifying current hepatitis C virus incidence in Egypt. *Journal of viral hepatitis*. 2013;20(9):666-7.
44. Derbala M, Chandra P, Amer A, John A, Sharma M, Amin A, *et al.* Reexamination of the relationship between the prevalence of hepatitis C virus and parenteral antischistosomal therapy among Egyptians resident in Qatar. *Clinical and experimental gastroenterology*. 2014;7:427-33.
45. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013); Do they differ in Egypt? *Liver international : official journal of the International Association for the Study of the Liver*. 2014.
46. Benova L, Awad SF, Miller FD, Abu-Raddad LJ. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. *Hepatology*. 2014.
47. Khamis HH, Farghaly AG, Shatat HZ, El-Ghitany EM. Prevalence of hepatitis C virus infection among pregnant women in a rural district in Egypt. *Tropical doctor*. 2014.
48. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(33):14757-62.
49. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, *et al.* HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. *Gut*. 2010;59(11):1554-60.
50. Lacombe K. Hepatitis C, from screening to treatment, a revolution. *Journal of the International AIDS Society*. 2014;17(4 Suppl 3):19499.
51. Metts J, Carmichael L, Kokor W, Scharffenberg R. Hepatitis C: prevalence, transmission, screening, and prevention. *FP essentials*. 2014;427:11-7.
52. Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, *et al.* Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. *World journal of gastroenterology : WJG*. 2014;20(43):15992-6013.
53. Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. *Asian journal of transfusion science*. 2014;8(1):19-25.

54. Khattab MA, Eslam M, Sharwae MA, Hamdy L. Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. *American journal of infection control*. 2010;38(8):640-1.
55. Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential weapon for the outbreak of blood borne viruses in the community. *Annals of medical and health sciences research*. 2013;3(2):177-81.
56. Serdar T, Derek L, Unic A, Marijancevic D, Markovic D, Primorac A, et al. Occupational exposures in healthcare workers in University Hospital Dubrava--10 year follow-up study. *Central European journal of public health*. 2013;21(3):150-4.
57. Paez Jimenez A, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, et al. Injection drug use is a risk factor for HCV infection in urban Egypt. *PloS one*. 2009;4(9):e7193.
58. Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, et al. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. *The Lancet Global health*. 2014;2(9):e541-9.
59. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015;61(1):77-87.
60. Nabi SG, Zaffar G, Sheikh NI, Hassan K, Hassan U. Hepatitis C virus genotypes: a plausible association with viral loads. *Indian journal of pathology & microbiology*. 2013;56(4):384-7.
61. Petruzzello A, Coppola N, Loquercio G, Marigliano S, Giordano M, Azzaro R, et al. Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. *Intervirology*. 2014;57(6):311-8.
62. Iles JC, Raghwan J, Harrison GL, Pepin J, Djoko CF, Tamoufe U, et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. *Virology*. 2014;464-465:233-43.
63. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? *Liver international : official journal of the International Association for the Study of the Liver*. 2012;32 Suppl 1:79-87.
64. Maruo R, Sato Y, Yokota H, Kageyama Y, Syukuya K, Yatomi Y. [Usefulness of hepatitis C virus (HCV) genotype test using direct sequencing of 5' untranslated region--application from 2003 to 2011]. *Rinsho byori The Japanese journal of clinical pathology*. 2012;60(10):927-31.
65. Shier MK, El-Wetidy MS, Ali HH, Al-Qattan MM. Characterization of hepatitis C virus genotypes by direct sequencing of HCV 5'UTR region of isolates from Saudi Arabia. *PloS one*. 2014;9(8):e103160.
66. Gervain J. [The diagnosis of hepatitis C virus infection]. *Orvosi hetilap*. 2014;155(26):1019-23.
67. Martins PP, Lampe E, Lewis-Ximenez LL, de Souza PS, Fernandes CA, Villar LM. Performance of molecular methods for hepatitis C virus diagnosis: usefulness among chronic cases and during the course of infection. *Clinical laboratory*. 2013;59(9-10):1031-9.
68. Casanova YS, Boeira Tda R, Sisti E, Celmer A, Fonseca AS, Ikuta N, et al. A complete molecular biology assay for hepatitis C virus detection, quantification and genotyping. *Revista da Sociedade Brasileira de Medicina Tropical*. 2014;47(3):287-94.
69. Chakravarty R. Diagnosis and monitoring of chronic viral hepatitis: serologic and molecular markers. *Frontiers in bioscience*. 2011;3:156-67.

70. Cobb B, Heilek G, Vilchez RA. Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies. *BMC infectious diseases*. 2014;14 Suppl 5:S8.
71. Goncalves Rossi LM, Rahal P. Challenges in molecular epidemiology of hepatitis C virus. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2014;60(2):174-6.
72. Josko D. Molecular virology in the clinical laboratory. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2010;23(4):231-6.
73. Zubkova NV, Filatova EV, Zubov SV. [Serological and molecular genetic markers of hepatitis C virus in infected donors]. *Voprosy virusologii*. 2010;55(5):34-6.
74. Al-Tahish G, El-Barrawy MA, Hashish MH, Heddaya Z. Effectiveness of three types of rapid tests for the detection of hepatitis C virus antibodies among blood donors in Alexandria, Egypt. *Journal of virological methods*. 2013;189(2):370-4.
75. Esteban JI, van Helden J, Alborino F, Burgisser P, Cellerai C, Pantaleo G, *et al*. Multicenter evaluation of the Elecsys(R) anti-HCV II assay for the diagnosis of hepatitis C virus infection. *Journal of medical virology*. 2013;85(8):1362-8.
76. Marwaha N, Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. *World journal of gastroenterology : WJG*. 2014;20(11):2948-54.
77. Bahadi A, Maoujoud O, Zejjari Y, Alayoud A, Hassani K, Elkabbaj D, *et al*. [Diagnosis and evaluation of hepatitis C virus among haemodialysis patients]. *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2013;19(2):192-9.
78. Schiavon Lde L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. *World journal of gastroenterology : WJG*. 2014;20(11):2854-66.
79. Gambato M, Lens S, Fernandez-Carrillo C, Alfaro I, Fornis X. Viral hepatitis and liver transplantation: pathogenesis, prevention and therapy of recurrent disease. *Digestive diseases*. 2014;32(5):538-44.
80. Petta S, Craxi A. Current and future HCV therapy: do we still need other anti-HCV drugs? *Liver international : official journal of the International Association for the Study of the Liver*. 2015;35 Suppl 1:4-10.
81. Shiffman ML, Benhamou Y. Cure of HCV related liver disease. *Liver international : official journal of the International Association for the Study of the Liver*. 2015;35 Suppl 1:71-7.
82. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. *Nature reviews Microbiology*. 2013;11(7):482-96.
83. Chavez-Tapia NC, Barrientos-Gutierrez T, Uribe M. Assessment of outcomes of hepatitis C treatment. *Jama*. 2014;312(23):2570-1.
84. Hunyady B, Gervain J, Horvath G, Makara M, Par A, Szalay F, *et al*. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. *Orvosi hetilap*. 2014;155 Suppl:3-24.
85. Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, *et al*. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. *Hepatology international*. 2013;7(2):533-8.

86. Chen H, Zhang Y, Huang P, Xu Y, Wang J, Su J, *et al.* Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. *Journal of biomedical research.* 2014;28(6):476-83.
87. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, *et al.* Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2014;58(8):1064-71.
88. Serfaty L. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals. *Liver international : official journal of the International Association for the Study of the Liver.* 2015;35 Suppl 1:18-20.
89. Jeong SW, Choi Y, Kim J. Management of viral hepatitis in liver transplant recipients. *Clinical and molecular hepatology.* 2014;20(4):338-44.
90. Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA, *et al.* Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. *Global public health.* 2014:1-22.
91. Aly Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the Oral Therapy, What Do We Know About HCV-4 in Egypt: A Randomized Survey of Prevalence and Risks Using Data Mining Computed Analysis. *Medicine.* 2014;93(28):e204.
92. Centers for Disease C, Prevention. Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. *MMWR Morbidity and mortality weekly report.* 2012;61(29):545-9.
93. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? *Liver international : official journal of the International Association for the Study of the Liver.* 2015;35 Suppl 1:27-34.
94. Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection. *Liver international : official journal of the International Association for the Study of the Liver.* 2015;35 Suppl 1:56-64.
95. Bodeau S, Nguyen-Khac E, Solas C, Bennis Y, Capron D, Duverlie G, *et al.* Patients treated with first-generation HCV protease inhibitors exhibits high ribavirin concentrations. *Journal of clinical pharmacology.* 2014.
96. Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, *et al.* Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.* 2014.
97. Cortez KJ, Kottlil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. *Therapeutic advances in chronic disease.* 2015;6(1):4-14.
98. Farkkila M. [New drugs for hepatitis C]. *Duodecim; laaketieteellinen aikakauskirja.* 2014;130(18):1813-22.
99. Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, *et al.* HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil. *PloS one.* 2014;9(1):e86413.
100. Sacchini D, Craxi L, Refolo P, Minacori R, Cicchetti A, Gasbarrini A, *et al.* Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014.

101. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, *et al.* The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. *Journal of viral hepatitis*. 2015;22 Suppl 1:26-45.

102. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. *Pharmacogenomics and personalized medicine*. 2014;7:387-98.

103. Vagu C, Sultana C, Ruta S. Understanding the molecular targets for new therapeutical agents in hepatitis c infection. *Roumanian archives of microbiology and immunology*. 2013;72(1):5-24.

104. Pan Q, van der Laan LJ. New targets for treatment against HCV infection. *Best practice & research Clinical gastroenterology*. 2012;26(4):505-15.

105. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing. *Journal of hepatology*. 2014;61(1S):S34-S44.

106. Zingaretti C, De Francesco R, Abrignani S. Why is it so difficult to develop a hepatitis C virus preventive vaccine? *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2014;20 Suppl 5:103-9.

107. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, *et al.* Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. *European journal of immunology*. 2014.

108. Ullah S, Shah MA, Riaz N. Recent Advances in Development of DNA Vaccines Against Hepatitis C virus. *Indian journal of virology : an official organ of Indian Virological Society*. 2012;23(3):253-60.

109. Verma R, Khanna P, Chawla S. Hepatitis C vaccine. *Human vaccines & immunotherapeutics*. 2014;10(7):1927-9.

110. Bill RM. Recombinant protein subunit vaccine synthesis in microbes: a role for yeast? *The Journal of pharmacy and pharmacology*. 2014.

111. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, *et al.* A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. *Science translational medicine*. 2014;6(261):261ra153.

112. Verma R, Khanna P, Chawla S. Hepatitis C vaccine: Need of the hour. *Human vaccines & immunotherapeutics*. 2014;10(8).

113. Beaumont E, Roingard P. [Towards a bivalent prophylactic vaccine against hepatitis B and C viruses?]. *Medicine sciences : M/S*. 2014;30(1):33-5.

114. Saitoh A, Okabe N. Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap". *Vaccine*. 2014;32(34):4253-8.

115. Global Advisory Committee on Vaccine Safety, 11-12 June 2014. *Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations*. 2014;89(29):325-35.

116. [Insulin resistance disturbances in patients with HCV infection]. *Georgian medical news*. 2012(211):43-5.

117. Gentilucci UV, Picardi A, Pozzilli P. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis: response to Lecube *et al.* *Diabetes care*. 2006;29(11):2558-9; author reply 9-60.

118. Huang JF, Yu ML, Dai CY, Chuang WL. Glucose abnormalities in hepatitis C virus infection. *The Kaohsiung journal of medical sciences*. 2013;29(2):61-8.
119. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. *Diabetes care*. 2004;27(5):1171-5.
120. Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. *Diabetes care*. 2006;29(5):1140-9.
121. Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? *Journal of hepatology*. 2006;45(4):514-9.
122. Petta S, Camma C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. *Liver international : official journal of the International Association for the Study of the Liver*. 2011;31(4):507-15.
123. Souza AF, Pace FH, Chebli JM, Ferreira LE. Insulin resistance in non-diabetic patients with chronic hepatitis C: what does it mean? *Arquivos brasileiros de endocrinologia e metabologia*. 2011;55(6):412-8.
124. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. *World journal of diabetes*. 2014;5(1):52-8.
125. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, *et al*. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. *Journal of gastroenterology and hepatology*. 2013.
126. Delgado-Borrego A, Kamegaya Y, Jordan SH, Agrawal S, Valim C, Chung RT. HCV synergizes with body weight in the promotion of insulin resistance. *Journal of viral hepatitis*. 2011;18(2):135-41.
127. Goossens N, Negro F. Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. *Reviews on recent clinical trials*. 2014.
128. Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, *et al*. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance. *Journal of gastroenterology*. 2014;49(2):317-23.
129. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. *Hepatology international*. 2013;7(Suppl 2):782-9.
130. Peres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Peres LD. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. *Annals of hepatology*. 2013;12(6):871-5.
131. Ziada DH, El Saadany S, Enaba M, Ghazy M, Hasan A. The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie*. 2012;26(6):325-9.
132. Das GC, Hollinger FB. Molecular pathways for glucose homeostasis, insulin signaling and autophagy in hepatitis C virus induced insulin resistance in a cellular model. *Virology*. 2012;434(1):5-17.
133. Wojcik K, Jablonowska E, Omulecka A, Piekarska A. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. *World journal of gastroenterology : WJG*. 2014;20(30):10449-56.

134. Zheng YY, Wang LF, Fan XH, Wu CH, Huo N, Lu HY, *et al.* Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C. *Journal of viral hepatitis*. 2013;20(4):273-80.
135. del Campo JA, Garcia-Valdecasas M, Rojas L, Rojas A, Romero-Gomez M. The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. *PloS one*. 2012;7(10):e47904.
136. Milner KL, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, *et al.* Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. *Journal of viral hepatitis*. 2014;21(5):325-32.
137. Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. *Diabetes care*. 2012;35(5):1090-4.
138. Chan CH, Hansen RD, Gilliver RS, Jones BE. Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance. *Internal medicine journal*. 2013;43(6):656-62.
139. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. *The American journal of gastroenterology*. 2005;100(7):1509-15.
140. Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, *et al.* The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. *Clinical and molecular hepatology*. 2014;20(1):38-46.
141. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, *et al.* Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. *The American journal of gastroenterology*. 2007;102(3):570-6.
142. Khatlab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *The American journal of gastroenterology*. 2010;105(9):1970-7.
143. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, *et al.* Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance. *Gut and liver*. 2009;3(2):108-15.
144. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, *et al.* Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. *Gut*. 2009;58(12):1662-9.
145. Simo R, Lecube A, Genesca J, Esteban JI, Hernandez C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. *Diabetes care*. 2006;29(11):2462-6.
146. Chayama K, Hayes CN. Interleukin-28B polymorphisms and hepatitis C virus clearance. *Genome medicine*. 2013;5(1):6.
147. Canadian Diabetes Association Clinical Practice Guidelines Expert C, Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. *Canadian journal of diabetes*. 2013;37 Suppl 1:S8-11.
148. Enes P, Martin-Frias M, Alvarez MA, Yelmo R, Alonso M, Barrio R. Achievement of metabolic control goals set by the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes in pediatric patients with type 1 diabetes from Spain. *Diabetes research and clinical practice*. 2014.

149. Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Fery F, *et al.* Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. *Diabetologia*. 2010;53(1):36-44.
150. Ye F, Tao R, Cong W, Tian J, Liu Q. Utilization of fluorescence tracer in hyperinsulinemic-euglycemic clamp test in mice. *Journal of biochemical and biophysical methods*. 2008;70(6):978-84.
151. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, De Francisco A, *et al.* Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. *BMC endocrine disorders*. 2013;13:47.
152. Morimoto A, Tatsumi Y, Soyano F, Miyamatsu N, Sonoda N, Godai K, *et al.* Increase in homeostasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion: the Saku study. *PloS one*. 2014;9(8):e105827.
153. Huang R, Su Z, Zhao Z, Kong W, Mai Y, She W, *et al.* [Diagnosis boundary values of metabolic syndrome obesity index for Children and adolescents]. *Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences*. 2014;39(7):718-22.
154. Mohamed NA, Rashid ZZ, Wong KK. Hepatitis C virus genotyping methods: evaluation of AmpliSens(R) HCV-1/2/3-FRT compared to sequencing method. *Journal of clinical laboratory analysis*. 2014;28(3):224-8.
155. Cheng A, Qian Q, Kirby JE. Evaluation of the Abbott RealTime CT/NG assay in comparison to the Roche Cobas Amplicor CT/NG assay. *Journal of clinical microbiology*. 2011;49(4):1294-300.
156. Hsieh MY, Lee LP, Hou NJ, Yang JF, Huang JF, Dai CY, *et al.* Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0. *The Kaohsiung journal of medical sciences*. 2007;23(7):332-8.
157. Freckmann G, Schmid C, Baumstark A, Pleus S, Link M, Haug C. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 15197. *Journal of diabetes science and technology*. 2012;6(5):1060-75.
158. Mohamadnejad M, Tavangar SM, Sotoudeh M, Kosari F, Khosravi M, Geramizadeh B, *et al.* Histopathological Study of Chronic Hepatitis B: A Comparative Study of Ishak and METAVIR Scoring Systems. *International journal of organ transplantation medicine*. 2010;1(4):171-6.
159. Crawford DH, Dore GJ, Sievert W, Cheng WS, Weltman M, McCaughan G, *et al.* Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. *Antiviral therapy*. 2012;17(5):849-54.
160. Rammeh S, Khadra HB, Znaidi NS, Romdhane NA, Najjar T, Bouzaidi S, *et al.* [Inter-observers agreement of Ishak and Metavir scores in histological evaluation of chronic viral hepatitis B and C]. *Annales de biologie clinique*. 2014;72(1):57-60.
161. Noworolski SM, Lam MM, Merriman RB, Ferrell L, Qayyum A. Liver steatosis: concordance of MR imaging and MR spectroscopic data with histologic grade. *Radiology*. 2012;264(1):88-96.

162. Luo J, Wen Q, Li J, Xu L, Chu S, Wang W, *et al.* Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma. *International journal of clinical and experimental pathology*. 2014;7(9):6117-24.
163. Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. *Journal of clinical pathology*. 2005;58(6):645-9.
164. Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. *Journal of gastroenterology and hepatology*. 2009;24(1):42-8.
165. Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? *Hepatic medicine : evidence and research*. 2014;6:113-8.
166. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, *et al.* Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. *Gastroenterology*. 2008;134(2):416-23.
167. El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. *World journal of gastroenterology : WJG*. 2012;18(3):212-24.
168. Romero-Gomez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM, *et al.* Treatment of insulin resistance with metformin in naive chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology*. 2009;50(6):1702-8.
169. Petta S, Camma C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, *et al.* Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. *Antiviral therapy*. 2009;14(5):631-9.
170. Lonardo A, Ballestri S, Adinolfi LE, Violi E, Carulli L, Lombardini S, *et al.* Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie*. 2009;23(4):273-8.
171. Park SK, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, *et al.* Change of insulin sensitivity in hepatitis C patients with normal insulin sensitivity: a 5-year prospective follow-up study variation of insulin sensitivity in HCV patients. *Internal medicine journal*. 2010;40(7):503-11.
172. Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. *Diabetes care*. 2006;29(5):1096-101.
173. Saludes V, Gonzalez V, Planas R, Matas L, Ausina V, Martro E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. *World journal of gastroenterology : WJG*. 2014;20(13):3431-42.
174. Kawaguchi Y, Mizuta T. Interaction between hepatitis C virus and metabolic factors. *World journal of gastroenterology : WJG*. 2014;20(11):2888-901.
175. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with chronic hepatitis C and insulin resistance. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2012;16(6):e436-41.
176. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, *et al.* Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. *Liver international : official journal of the International Association for the Study of the Liver*. 2010;30(3):447-54.

-
177. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. *Hepatology*. 2012;56(2):464-73.
178. Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, *et al*. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. *Liver international : official journal of the International Association for the Study of the Liver*. 2010;30(3):479-86.
179. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, *et al*. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. *The Journal of clinical endocrinology and metabolism*. 2011;96(8):2601-8.
180. Mohamed HR, Abdel-Azziz MY, Zalata KR, Abdel-Razik AM. Relation of insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. *International journal of health sciences*. 2009;3(2):177-86.

المخلص العربي

يقدر عدد مرضى الإلتهاب الكبدي الفيروسي سي بحوالي 170 مليون نسمة، يمثلون حوالي 3% من سكان العالم. الإلتهاب الكبدي الفيروسي هو أهم مشكلة صحية عامة تواجه مصر اليوم. وتقدر معدلات انتشار فيروس (سي) في عموم السكان ما بين 10% و 15% في المناطق الريفية، مع بعض الفئات العمرية الذين يعانون من معدلات انتشار تصل إلى 50%. ومنذ عام 2006 حققت مصر تقدماً كبيراً في السيطرة على الإلتهاب الكبدي الفيروسي حيث أسست لجنة وطنية لمكافحة الإلتهاب الكبدي الفيروسي مكونة من 23 وحدة علاج الإلتهاب الكبدي الفيروسي موزعة على كافة أنحاء البلاد كجزء من برنامج الحملة القومية لعلاج هذا المرض والذي أطلق في عام 2008. وبين عامي 2006 و 2012 تم علاج أكثر من 220000 مريض في مراكز العلاج القومية وعيادات التأمين الصحي. و تتم حالياً معالجة المرضى المصريين المصابين بفيروس سي عن طريق تلقي 48 جرعة أسبوعية تحت الجلد من الإنترفيرون مع جرعة مرتين يومياً من عقار ريبافيرين، مع العلم أن مخططات العلاج الجديد بعقار سوفسوفير في طريقها للتنفيذ.

في عام 1994 و للمرة الأولى ذكرت تقارير لأليسون و آخرون انه يوجد علاقة بين مرض السكري النوع الثاني والإلتهاب الكبدي المزمن ، حيث لاحظ أن انتشار مرض السكري النوع الثاني كان أعلى بكثير في حالات تليف الكبد المتعلقة بالإلتهاب الكبدي الفيروسي سي من تلك المصاحبة لتليف الكبد الناتج عن أمراض الكبد الأخرى. و لقد تمت دراسة الأدلة التي تظهر تأثير الإلتهاب الكبدي الفيروسي سي في تسبب مرض السكري وكذلك تأثيره المناعي من خلال تحفيز استجابة الخلايا للمفاوية TH1 و التي بدورها تعمل على تنشيط عامل (TNF) نظام α - وارتفاع مستويات انترلوكين 6. إن الأنسولين يؤثر بيولوجياً من خلال تحفيز مستقبلات الأنسولين 1 (IRS-1) و 2 (IRS-2). إن وجود مستويات عالية من $\text{TNF-}\alpha$ يكون أحد القواعد الأساسية لمقاومة الأنسولين (IR)، والتي تعمل من خلال التأثير على التيروزين الداخلى في تكوين مستقبلات الأنسولين (IRS-1)، وهو جزيء أساسي في تحفيز إفراز الأنسولين.

العلاقة بين الإلتهاب الكبدي الفيروسي سي و مقاومة الأنسولين لها عواقب سريرية كبيرة. أدلة متزايدة تشير إلى أن مقاومة الأنسولين المصاحبة للإلتهاب الكبدي الفيروسي سي قد تسبب تسارع تليف الكبد، وانخفاض الاستجابة للعلاج بالإنترفيرون و سرعة الإصابة بسرطان الكبد. وترتبط زيادة مستويات مقاومة الأنسولين مع انخفاض معدلات الاستجابة الفيروسية الأولية للعلاج وكذلك الاستجابة الفيروسية المستمرة في مرضى الإلتهاب الكبدي المزمن الذين يعالجون بمزيج من الإنترفيرون و عقار ريبافيرين. وهذا يعني أن وجود حالات من مقاومة الأنسولين قبل الإصابة بمرض السكري يجب أن يتم تشخيصها حيث يعتبر تحليل (HOMA-IR) وسيلة سهلة لتشخيص مثل تلك الحالات.

لقد كان هدفنا تقييم مدى انتشار مقاومة الأنسولين لدى المرضى المصريين المصابين بالنمط الجيني 4 لفيروس التهاب الكبد المزمن سي، وتقييم العوامل المرتبطة بمقاومة الأنسولين في هؤلاء المرضى واختبار تأثير مقاومة الأنسولين على نتائج العلاج.

وكان معدل HOMA-IR بالمرضى $3.0 > 31\%$ ، ومتوسط مؤشر كتلة الجسم للمائة مريض المصابين بالتهاب الكبد المزمن و المدرجين بالدراسة كان 27.60 ± 27.06 مع متوسط $3.44 \pm SD$ ، وكانت متلازمة التمثيل الغذائي موجودة في 15% منهم. أما بالنسبة للدراسة المناعية و الهستوكيميائية ل IRS-1 في 29 عينة للكبد مختارة من هؤلاء المرضى: 15 حالة أظهرت صبغة ضعيفة ل 10-50% أو أقل من خلايا الكبد وأظهرت 14 حالة صبغة قوية ل 50% أو أكثر من خلايا الكبد.

وأظهرت دراسة العلاقة بين مقاومة الأنسولين ، العمر، مؤشر كتلة الجسم، كمية الـ HCV-RNA قبل العلاج فى الدم ، معدلات الدهون، مرحلة التليف الكبدي و درجة دهون الكبد فروق ذات دلالة إحصائية بين HOMA-IR والمستوى الفيروسي المبدئي ومرحلة التليف الكبدي و ذلك عندما تم تحليل البيانات بواسطة الانحدار الخطي متعدد المتغيرات، وتشير النتائج إلى أن المستوى الفيروسي المبدئي بقي العامل المستقل الوحيد المرتبط بارتفاع معدل HOMA-IR ($p = 0.001$). أما بالنسبة لتحليل أحادي المتغير من المتغيرات التي تؤثر على نتائج العلاج كشفت هذه الدراسة أن في سن أصغر، انخفاض درجات HOMA-IR ، وانخفاض مستوى خط الأساس RNA-HCV والدرجات القليلة من دهون الكبد، ارتبطت بشكل كبير مع الاستجابة للعلاج لدى المرضى المدرجين بهذه الدراسة. وأظهر التحليل متعدد المتغيرات اللوجستي أن المستوى الفيروسي الأساسي المنخفض بالدم بقي العامل المستقل الوحيد المرتبط بالاستجابة للعلاج.

وتبين هذه النتائج أن الإصابة بمرض التهاب الكبد المزمن بفيروس سي النمط الجيني 4 يكون مصحوب بارتفاع معدل انتشار مقاومة الأنسولين. و يظهر أيضا أن المرضى الذين يعانون من مقاومة الأنسولين أكثر عرضة لفشل العلاج بألفا انترفيرون مع عقار ريبافيرين. و يظهر أيضا أن مقاومة الانسولين تتحسن مع العلاج الناجح.